The effect of tanimilast on exacerbation rate reduction in the subgroup of chronic bronchitis patients with higher blood eosinophil counts is consistent with previous results with the oral PDE4 inhibitor roflumilast. The gene discussed is PDE4A; the disease is chronic bronchitis.